|1.||Jonas, Jost B: 43 articles (01/2013 - 09/2002)|
|2.||Sakamoto, Taiji: 22 articles (06/2014 - 02/2003)|
|3.||Jonas, J B: 22 articles (03/2007 - 09/2000)|
|4.||Kreissig, Ingrid: 18 articles (01/2009 - 09/2002)|
|5.||Scott, Ingrid U: 14 articles (09/2015 - 10/2003)|
|6.||Degenring, Robert F: 14 articles (08/2006 - 09/2002)|
|7.||Kreissig, I: 12 articles (01/2006 - 01/2003)|
|8.||Ozdemir, Hakan: 11 articles (01/2013 - 03/2004)|
|9.||Gillies, Mark C: 11 articles (01/2013 - 05/2003)|
|10.||Karacorlu, Murat: 11 articles (01/2013 - 03/2004)|
07/01/2004 - "This information may be helpful in determining the optimal dosage of intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular edema."
05/01/2008 - ": To determine safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for refractory clinically significant diabetic macular edema (DME). "
05/01/2005 - "A single injection of 4 mg of intravitreal triamcinolone acetonide effectively reduces the foveal thickness in diabetic macular edema and improves visual acuity, but there does not appear to be a strong correlation between the reduction of foveal thickness and the improvement in visual acuity."
03/01/2010 - "Intravitreal triamcinolone acetonide showed to be effective for improving visual acuity in patients with diabetic macular edema, in the first three months of treatment. "
08/01/2005 - "Intravitreal triamcinolone acetonide is an effective treatment for serous macular detachment in patients with diabetic macular edema."
|2.||Macular Degeneration (Age-Related Maculopathy)
06/01/2001 - "Animal models, in vitro assays and pilot clinical studies suggest that intravitreal triamcinolone acetonide may be useful in the treatment of age-related macular degeneration. "
09/01/2000 - "Whilst animal studies and a pilot clinical trial suggest that intravitreal triamcinolone acetonide (TA) may be useful in the treatment of age-related macular degeneration (AMD), its mode of action remains to be fully elucidated. "
01/01/2006 - "To evaluate the efficacy of sub-Tenon's injection of triamcinolone acetonide for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). "
01/01/2000 - "Intravitreal triamcinolone acetonide may provide short-term improvement in visual acuity and fundus findings in exudative macular degeneration. "
01/01/2012 - "To evaluate the effects of intravitreal triamcinolone acetonide (TA) as a monotherapy of serous Pigment Epithelial Detachment (PED) associated with AMD (Age-Related Macular Degeneration), this study has been performed. "
|3.||Retinal Vein Occlusion
01/01/2008 - "To assess the long-term safety and efficacy of intravitreal triamcinolone acetonide injection in the management of macular oedema caused by central, hemi-, and branch retinal vein occlusion (CRVO, HRVO, or BRVO). "
11/01/2008 - "This study demonstrates a benefit associated with intravitreal triamcinolone acetonide injection for retinal vein occlusions that was maintained by patients with branch retinal vein occlusions and hemiretinal vein occlusions over a 12-month period. "
01/01/2008 - "The aim of the study was to evaluate the safety and effectiveness of trans-Tenon's retrobulbar triamcinolone acetonide (TA) injection for macular oedema associated with branch retinal vein occlusion (BRVO). "
10/01/2012 - "Intravitreal triamcinolone acetonide may improve macular sensitivity and morphology in patients with ischemic and nonischemic branch retinal vein occlusion."
02/01/2011 - "Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion."
06/03/2015 - "The 40-mg dose of FX006 produced pain relief that was improved at two through twelve weeks and was significantly superior to immediate-release triamcinolone acetonide at five to ten weeks (p < 0.05 at each time point). "
06/03/2015 - "The 10-mg dose of FX006 produced pain relief that was improved relative to immediate-release triamcinolone acetonide at two through twelve weeks, although the difference in pain relief was not significant (p ≥ 0.05). "
04/20/2009 - "SIJ blocks with triamcinolone acetonide are beneficial for some patients with SIJ pain without spondyloarthropathy. "
06/03/2015 - "The present study was undertaken to determine if FX006, an extended-release formulation of triamcinolone acetonide, can provide pain relief that is superior to the current standard of care, immediate-release triamcinolone acetonide. "
04/20/2009 - "The study aimed to investigate the therapeutic efficacy of sacroiliac joint (SIJ) blocks with triamcinolone acetonide in patients with SIJ pain without spondyloarthropathy. "
11/01/2013 - "Intracameral triamcinolone acetonide was highly effective in controlling postoperative inflammation in phacotrabeculectomy, and triamcinolone acetonide 1.0 mg provided the best postoperative result. "
11/01/2013 - "Intracameral injection of triamcinolone acetonide in phacotrabeculectomy resulted in a significant reduction in aqueous inflammation and improvement in visual acuity."
05/01/2008 - "Intravitreal triamcinolone acetonide is effective in treating various ocular disorders associated with inflammation and swelling of the retina. "
04/01/2012 - "Supratarsal injection of triamcinolone acetonide is effective and safe in patients with severe chronic allergic keratoconjunctivits to relieve severe inflammation associated with this disease."
07/01/2006 - "Posterior subtenon injection of triamcinolone acetonide proved to be a safe and effective way of treating intraocular inflammations."
|4.||Triamcinolone Acetonide (Azmacort)
|7.||Adrenal Cortex Hormones (Corticosteroids)
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)